BMO starts coverage on Integra with $19 target

0 min read     Updated on 09 Jul 2026, 10:49 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

BMO Capital analyst Vik Chopra has initiated coverage on Integra Lifesciences (NASDAQ: IART) with a Market Perform rating and a price target of $19, establishing a new valuation benchmark for the medical technology company.

powered bylight_fuzz_icon
45082858

*this image is generated using AI for illustrative purposes only.

BMO Capital analyst Vik Chopra has initiated coverage on Integra Lifesciences (NASDAQ: IART) with a Market Perform rating and a price target of $19. This new assessment provides a fresh valuation perspective on the medical technology company's stock performance.

Rating and Target Details

The brokerage firm's decision to assign a Market Perform rating suggests a balanced view of the stock's potential relative to the broader market. The price target of $19 establishes a specific valuation benchmark for investors monitoring the company.

Metric Value
Rating Market Perform
Price Target $19
Exchange NASDAQ
Ticker Symbol IART

What specific catalysts could drive Integra Lifesciences' stock above the $19 price target?

How might upcoming clinical trial results influence future analyst ratings for IART?

What are the potential risks that could lead to a downgrade from the current Market Perform rating?

like19
dislike

Integra LifeSciences appoints Topaz Kirlew chief regulatory officer

1 min read     Updated on 02 Jul 2026, 08:27 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Integra LifeSciences Holdings Corporation appointed Topaz Kirlew as corporate vice president and chief regulatory officer. Kirlew will lead global regulatory affairs, strategy, and compliance. She brings over 35 years of industry experience.

powered bylight_fuzz_icon
44549840

*this image is generated using AI for illustrative purposes only.

Integra LifeSciences Holdings Corporation appointed Topaz Kirlew, DBA, MBA, as corporate vice president and chief regulatory officer to strengthen its regulatory capabilities. Kirlew will lead the global regulatory affairs organization and oversee regulatory strategy, compliance, submissions, and transformation initiatives worldwide. The appointment follows her tenure as the interim regulatory leader, where she managed active submissions and led risk mitigation efforts.

Stuart Essig, chairman and chief executive officer of Integra LifeSciences, highlighted Kirlew's experience and judgment. He stated that she has earned the confidence of the leadership team and will help advance the company's mission of restoring patients' lives.

Professional Background

Since joining Integra in 2021, Kirlew has played a key role in building the company's regulatory capabilities. She brings more than 35 years of experience in the healthcare and medical technology industry, spanning regulatory affairs, quality, operations, and clinical functions.

Prior to joining Integra, Kirlew held positions at several organizations, including Danaher Corporation, Apyx Medical, Bio-Tissue, and the University of Miami's Diabetes Research Institute. She began her career as a clinical laboratory scientist at institutions such as the National Institutes of Health, Georgetown University Hospital, and the University of Maryland Medical Center.

Education

Kirlew earned a bachelor’s degree in clinical laboratory science from Florida International University. She holds a master’s degree and a doctorate in business administration from Nova Southeastern University's School of Business and Entrepreneurship.

How will Kirlew's appointment influence Integra's regulatory strategy for upcoming product submissions?

What specific regulatory transformation initiatives does Kirlew plan to implement?

How might this leadership change impact Integra's timeline for bringing new medical technologies to market?

like17
dislike

More News on Integra Lifesciences Holdings Corp